more

AbbVie (ABBV)

(Delayed Data from NYSE)

$173.61 USD

+1.29 (0.75%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Roche (RHHBY) Beats on Earnings in 2016, Misses on Sales

by Zacks Equity Research Published on February 02,2017

Roche beat on earnings but missed on sales in 2016 due to decline in sales of Lucentis, Pegasys, Avastin and Tarceva.

AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada

by Zacks Equity Research Published on February 02,2017

AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.

Key Takeaways from AbbVie's Q4 Call: Humira and the Pipeline

by Arpita Dutt Published on January 30,2017

2017 will be a year of significant R&D investment for AbbVie (ABBV) as well as several late-stage readouts which will give an insight into the company's long term growth prospects.

Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

by Zacks Equity Research Published on January 30,2017

Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

Amgen Wins Favorable CHMP Opinion for Humira Biosimilar

by Zacks Equity Research Published on January 30,2017

Amgen (AMGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the company's marketing authorization application (MAA) for ABP 501.

AbbVie (ABBV) Q4 Earnings Meet Estimates, Revenues Lag

by Zacks Equity Research Published on January 27,2017

AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

AbbVie (ABBV) Reports In-Line Q4 Earnings, Revenues Miss

by Zacks Equity Research Published on January 27,2017

AbbVie (ABBV) reported earnings of $1.20 in the fourth-quarter of 2016, with revenues coming in at $6.80 billion.

ABBVPositive Net Change

Friday's Best Earnings Charts

by Tracey Ryniec Published on January 26,2017

It's not easy to beat the estimate nearly every quarter.

Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft

by Zacks Equity Research Published on January 26,2017

Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.

AbbVie's HCV Regimen Okayed for Accelerated Assessment

by Zacks Equity Research Published on January 25,2017

AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).

Sunesis Offers Updates on SNS-062 and Qinprezo Programs

by Zacks Equity Research Published on January 24,2017

Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).

Can AbbVie (ABBV) Spring a Surprise This Earnings Season?

by Zacks Equity Research Published on January 24,2017

AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.

Gilead (GILD) HCV Therapy Application Validated in Europe

by Zacks Equity Research Published on January 23,2017

Gilead Sciences, Inc. (GILD) announced that its MAA for once-daily, single tablet regimen of Sovaldi, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for HCV treatment has been fully validated.

What's in Store for Abbott Labs (ABT) This Earnings Season?

by Zacks Equity Research Published on January 20,2017

Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.

Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

by Zacks Equity Research Published on January 20,2017

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

4 Drug Stocks Poised to Surprise this Earnings Season

by Zacks Equity Research Published on January 20,2017

Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.

Celgene (CELG) Q4 Earnings: Will the Stock Pull a Surprise?

by Zacks Equity Research Published on January 20,2017

Celgene Corporation (CELG), which is set to report fourth-quarter 2016 results on Jan 26, reported a positive earnings surprise of 6.11% last quarter.

Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication

by Zacks Equity Research Published on January 20,2017

AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).